Inside Innovation

Cellular therapy company Lyell Immunopharma is investing $50 million in a new 70,000 square foot manufacturing facility located in Bothell, Washington. This investment will support

CorneaGen, a Seattle-based provider of corneal transplant tissue, committed to donating $100,000 to help fund corneal transplant surgeries for underprivileged people of color in need

The University of Washington and Seattle-based HDT Bio Corp. announced the development of a promising COVID-19 vaccine candidate that uses a cutting-edge approach. Based on

Seattle-based biotech research startup A-Alpha Bio has received an $800,000 grant from the Bill & Melinda Gates Foundation that will support drug research for treating

“I think the most important thing in building a company and the thing that we want inside Sana is finding a mission that will change

Seattle Genetics and Genmab, a Danish biotechnology company, announced a 24% response rate for their joint cervical cancer medication tisotumab vedotin, paving the way for

Sana Biotechnology, a Seattle-based company developing cell and gene therapies, announced it has raised more than $700 million to aid in the discovery and development

Bothell, Washington’s Ventec Life Systems partnered with General Motors to rapidly scale their ventilator manufacturing capabilities during the onset of COVID-19. They are on track

Seattle-based Alpine Immune Sciences announced a $60M licensing agreement with AbbVie Inc. for its ALPN-101 midstage lupus and autoimmune asset. Under the pact, AbbVie grabs

Biomedical Advanced Research and Development Authority (BARDA) announced a collaboration with Seattle’s Immunexpress Inc. to determine the risk of sepsis in hospitalized COVID-19 patients. READ

Adaptive Biotechnologies and Microsoft announced a new project to address COVID-19, called ImmuneCODE. The project tracks how the immune system fights COVID-19 and aims to

Athira Pharma, a Seattle-based biotechnology company, secured $85 million in a Series B round. The additional financing will support Athira Pharma’s Phase 2/3 Alzheimer’s clinical